PMID- 33920381
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210518
IS  - 2075-1729 (Print)
IS  - 2075-1729 (Electronic)
IS  - 2075-1729 (Linking)
VI  - 11
IP  - 4
DP  - 2021 Apr 11
TI  - Evaluation of the Impact of Different Pain Medication and Proton Pump Inhibitors 
      on the Osteogenic Differentiation Potential of hMSCs Using (99m)Tc-HDP Labelling.
LID - 10.3390/life11040339 [doi]
LID - 339
AB  - First-line analgetic medication used in the field of musculoskeletal degenerative 
      diseases, like Nonsteroidal anti-inflammatory drugs (NSAIDs), reduces pain and 
      prostaglandin synthesis, whereby peptic ulcers are a severe adverse effect. 
      Therefore, proton pump inhibitors (PPI) are frequently used as a concomitant 
      medication to reduce this risk. However, the impact of NSAIDs or metamizole, in 
      combination with PPIs, on bone metabolism is still unclear. Therefore, human 
      mesenchymal stem cells (hMSCs) were cultured in monolayer cultures in 10 
      different groups for 21 days. New bone formation was induced as follows: Group 1 
      negative control group, group 2 osteogenic differentiation media (OSM), group 3 
      OSM with pantoprazole (PAN), group 4 OSM with ibuprofen (IBU), group 5 OSM with 
      diclofenac (DIC), group 6 OSM with metamizole (MET), group 7 OSM with ibuprofen 
      and pantoprazole (IBU + PAN), group 8 OSM with diclofenac and pantoprazole (DIC + 
      PAN), group 9 OSM with metamizole and pantoprazole (MET + PAN) and group 10 OSM 
      with diclofenac, metamizole and pantoprazole (DIC + MET + PAN). Hydroxyapatite 
      content was evaluated using high-sensitive radioactive (99m)Tc-HDP labeling. 
      Within this study, no evidence was found that the common analgetic medication, 
      using NSAIDs alone or in combination with pantoprazole and/or metamizole, has any 
      negative impact on the osteogenic differentiation of mesenchymal stem cells in 
      vitro. To the contrary, the statistical results indicate that pantoprazole alone 
      (group 3 (PAN) (p = 0.016)) or diclofenac alone (group 5 (DIC) (p = 0.008)) 
      enhances the deposition of minerals by hMSCS in vitro. There is an ongoing 
      discussion between clinicians in the field of orthopaedics and traumatology as to 
      whether post-surgical (pain) medication has a negative impact on bone healing. 
      This is the first hMSC in vitro study that investigates the effects of pain 
      medication in combination with PPIs on bone metabolism. Our in vitro data 
      indicates that the assumed negative impact on bone metabolism is subsidiary. 
      These findings substantiate the thesis that, in clinical medicine, the patient 
      can receive every pain medication needed, whether or not in combination with 
      PPIs, without any negative effects for the osteo-regenerative potential.
FAU - Grossner, Tobias
AU  - Grossner T
AUID- ORCID: 0000-0001-8953-9384
AD  - Trauma Surgery and Paraplegiology, Clinic for Orthopedics and Trauma Surgery, 
      Center for Orthopedics, University Hospital Heidelberg, 69120 Heidelberg, 
      Germany.
FAU - Haberkorn, Uwe
AU  - Haberkorn U
AD  - Department of Nuclear Medicine, University Hospital Heidelberg, 69120 Heidelberg, 
      Germany.
AD  - Clinical Cooperation Unit Nuclear Medicine, Deutsches Krebsforschungszentrum 
      (DKFZ), 69120 Heidelberg, Germany.
AD  - Translational Lung Research Center Heidelberg (TLRC), German Center for Lung 
      Research (DZL), 69120 Heidelberg, Germany.
FAU - Gotterbarm, Tobias
AU  - Gotterbarm T
AD  - Department of Orthopedics and Traumatology, Kepler University Hospital, 4020 
      Linz, Austria.
LA  - eng
PT  - Journal Article
DEP - 20210411
PL  - Switzerland
TA  - Life (Basel)
JT  - Life (Basel, Switzerland)
JID - 101580444
PMC - PMC8069736
OTO - NOTNLM
OT  - 99mTc-HDP labeling
OT  - NSASIDs
OT  - hydroxyapatite
OT  - mesenchymal stem cells
OT  - metamizole
OT  - osteogenic differentiation
OT  - proton pump inhibitors
COIS- The authors declare no conflict of interest. The funders had no role in the 
      design of the study; in the collection, analyses, or interpretation of data; in 
      the writing of the manuscript, or in the decision to publish the results.
EDAT- 2021/05/01 06:00
MHDA- 2021/05/01 06:01
PMCR- 2021/04/11
CRDT- 2021/04/30 01:15
PHST- 2021/03/04 00:00 [received]
PHST- 2021/04/08 00:00 [revised]
PHST- 2021/04/09 00:00 [accepted]
PHST- 2021/04/30 01:15 [entrez]
PHST- 2021/05/01 06:00 [pubmed]
PHST- 2021/05/01 06:01 [medline]
PHST- 2021/04/11 00:00 [pmc-release]
AID - life11040339 [pii]
AID - life-11-00339 [pii]
AID - 10.3390/life11040339 [doi]
PST - epublish
SO  - Life (Basel). 2021 Apr 11;11(4):339. doi: 10.3390/life11040339.